NRC grant supports development of genetic biomarkers for cardiovascular disease

Vancouver, BC – Biotechnology company Med BioGene, which is developing genetic biomarkers for use in diagnosing and treating certain cancers and cardiovascular disease, says it has received a $307,000 grant from the National Research Council Canada Industrial Research Assistance Program (NRC-IRAP) to develop genetic biomarkers for cardiovascular disease (CVD).

“We believe that Med BioGene’s expertise in gene expression and the continued development and validation of our genetic signatures for CVD, coupled with access to world-class scientific knowledge and blood samples from patients with confirmed CVD through our collaboration with the University of Ottawa Heart Institute, will create an effective environment for the development of a novel tool for use in screening and in improving diagnosis, prognosis and treatment decisions for patients suffering from CVD” said Erinn Broshko, the company’s CEO.

“We are very pleased that NRC-IRAP has chosen to support such important research and development and we look forward to working closely with them throughout the project” he adds.